Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four other clinical trials being planned by the…

Source

Previous articleRed Light Holland Closes Acquisition of Cutting Edge Silicon Valley Applied Sciences Company Radix Motion, Becoming a Leader in Psychedelic Technology
Next articleThe Psyence Group Announces its Formal Entry into Jamaica with the Incorporation of its Wholly Owned Subsidiary, Psyence Jamaica Limited